Fulgent Genetics Inc
NASDAQ:FLGT

Watchlist Manager
Fulgent Genetics Inc Logo
Fulgent Genetics Inc
NASDAQ:FLGT
Watchlist
Price: 17.87 USD 5.43% Market Closed
Market Cap: 541.5m USD
Have any thoughts about
Fulgent Genetics Inc?
Write Note

Fulgent Genetics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fulgent Genetics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Fulgent Genetics Inc
NASDAQ:FLGT
Research & Development
-$48.7m
CAGR 3-Years
-32%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CVS Health Corp
NYSE:CVS
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cigna Corp
NYSE:CI
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Fulgent Genetics Inc
Glance View

Market Cap
545.7m USD
Industry
Health Care

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.

FLGT Intrinsic Value
14.58 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Fulgent Genetics Inc's Research & Development?
Research & Development
-48.7m USD

Based on the financial report for Sep 30, 2024, Fulgent Genetics Inc's Research & Development amounts to -48.7m USD.

What is Fulgent Genetics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-51%

Over the last year, the Research & Development growth was -28%. The average annual Research & Development growth rates for Fulgent Genetics Inc have been -32% over the past three years , -51% over the past five years .

Back to Top